|
Pat. No
|
Tumor volumes at baseline
|
Tumor volumes at relapse
|
|---|
| |
FET-1 (ml)
|
MRI-1 (ml)
|
Intersect FET-1 ∩ MRI-1 (ml)
|
Intersect FET-1 ∩ MRI-1 (% of FET-1)
|
FET-2 (ml)
|
MRI-2 (ml)
|
Intersect FET-2 ∩ MRI-2 (ml)
|
Intersect FET-2 ∩ MRI-2 (% of FET-2)
|
|---|
|
1
|
10.4
|
0.8
|
0.4
|
3.8
|
3.7
|
3.7
|
0.0
|
0
|
|
2
|
6.9
|
0.6
|
0.2
|
2.9
|
10.9
|
8.9
|
0.7
|
8.7
|
|
3
|
6.8
|
3.7
|
2.2
|
32.4
|
11.3
|
8.1
|
5.0
|
44.2
|
|
4
|
1.1
|
6.8
|
1.3
|
9.9
|
12.2
|
9.3
|
7.6
|
62.3
|
|
5
|
13.4
|
6.0
|
3.5
|
26.1
|
13.9
|
12.0
|
1.1
|
7.9
|
|
6
|
15.0
|
1.3
|
0.5
|
3.3
|
35.1
|
16.2
|
23.5
|
67.0
|
|
7
|
6.7
|
6.4
|
0.0
|
0.0
|
6.2
|
19.4
|
0.8
|
12.9
|
|
8
|
25.2
|
1.3
|
1.3
|
5.2
|
22.1
|
26.8
|
10.0
|
45.3
|
|
9
|
4.7
|
6.5
|
1.5
|
31.9
|
5.6
|
27.0
|
5.6
|
100
|
|
10
|
6.8
|
4.9
|
1.6
|
23.5
|
56.0
|
39.6
|
0.0
|
0.0
|
|
11
|
62.9
|
19.4
|
12.0
|
19.1
|
46.7
|
41.8
|
23.4
|
50.1
|
|
12
|
59.0
|
19.5
|
11.3
|
19.2
|
66.8
|
43.5
|
5.5
|
8.2
|
|
13
|
9.1
|
1.1
|
1.1
|
12.1
|
12.8
|
113.0
|
1.7
|
13.3
|
|
Mean
|
17.5
|
6.0
|
3.0
|
14.6
|
23.3
|
28.4
|
6.5
|
32.3
|
|
Median
|
9.1
|
4.9
|
1.3
|
12.1
|
12.8
|
19.4
|
5.0
|
13.3
|
|
SD
|
19.6
|
6.1
|
4.0
|
11.5
|
20.9
|
28.8
|
8.1
|
31.5
|
|
range
|
1.1–62.9
|
0.6–19.5
|
0–12
|
0–32.4
|
3.7–66.8
|
3.7–113
|
0–23.5
|
0-100.0
|
- FET-1: pathological FET-Volume in ml at baseline (post surgery)
- MRI-1: Gd-contrast-enhancement in ml at baseline (post surgery)
- FET-2: pathological FET-Volume in ml at the time of relapse
- MRI-1: Gd-contrast-enhancement in ml at the time of relapse
